Implicit Bioscience   Report issue

For profit Phase 2
Founded: Seattle WA United States (2004)

Organization Overview

First Clinical Trial
2017
NCT03017547
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Implicit Bioscience | Implicit Bioscience Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

ic14 (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Dengue (Phase 2)

Fever (Phase 2)

Motor Neuron Disease (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Sclerosis (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 1